The Ladders to Cures Accelerator, led by Dr. Anna Greka, aims to expedite drug development for multiple rare diseases by leveraging shared biological mechanisms. This innovative approach seeks to identify overlaps among rare diseases, potentially allowing single treatments to benefit various patient populations.
The Ladders to Cures Accelerator aims to develop treatments for multiple rare diseases through shared biological mechanisms. One drug, many rare diseases. Inside the movement to make rare drug development more profitable ... NIH funding cuts delayed a promising childhood brain cancer trial. Anna Greka has built her career on finding connections between different rare diseases. Greka, a Harvard professor and physician at Mass General Brigham, is also a member of the Broad Institute. At her lab, she oversees the Ladders to Cures Accelerator, an initiative designed to speed up the development of treatments for rare disease patients. Dr. Anna Greka's nodal biology approach looks for overlap across rare diseases, allowing a single treatment to potentially help patients with different diseases. By identifying areas where rare diseases overlap, Ladders to Cures hopes to develop new types of drugs that can be used to treat multiple conditions. By developing single drugs capable of treating multiple diseases, the addressable patient population of those drugs becomes much bigger.
Original title: “One drug, many rare diseases. Inside the movement to make rare drug development more profitable”